BJT-188 / Bluejay Therap - LARVOL DELTA

Bluejay Therapeutics Announces Upcoming Presentation of Preclinical Data in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at European Association for the Study of the Liver (EASL) Congress 2025 (GlobeNewswire) - "Bluejay Therapeutics...today announced it will present new preclinical data on the characterization of BJT-188...being investigated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), at the European Association for the Study of the Liver (EASL) Congress 2025, taking place May 7-10, 2025, in Amsterdam. ...The presentation of BJT-188 preclinical data represents an important milestone for Bluejay as we leverage our Liver-Targeting Advanced Platform (L-TAP) to expand our strategic focus beyond viral hepatitis into MASH, a serious liver disease with limited treatment options affecting millions globally."

Preclinical • Metabolic Dysfunction-Associated Steatohepatitis